1Chan AW, Bhatt DL,Chew DP,et al. Relation of inflammation and henefit of statins after percutaneous coronay interventions[J]. Circulation, 2003,107 (13) : 1750-1756.
2Wassmann S,Faul A. Rapid effect of 3-hydroxy-3-methyl glutayl coenzy-me a reductase inhibition on coronary endothelial function [J]. Circ Res,2003,93(9) :98-103.
3Marrti'nez Gonza'lez J,Raposo B,Rodriguez C,et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition prevents en dothelia NO synthase downregulation by atherogenic levels of na tive balance between transcriptional and postiranscriptional regu lation [J]. Arterioscler Thromb Vasc Biol, 2001,21 (5): 804-809.
4Mason JC, Ahmed Z, Mankoff R, et al. Statin induced expression of decay-accelerating factor protects vascular endothelium agaist eomplement-mediatel injury[J]. Circ Res, 2002,91 (8) : 696-703.
5Assmus B, Urbrich C, Aicher A,et al. HMG-CoA reductase inhibition reduce senescence and increase proliferation of endothelial progenitor cells vis regulation of cell cycle regulatory genes [J]. Circ Res, 2003,92 (9) : 1049-1055.
10Tohru Fukai, Martin R, Siegfried,et al. Regulation of the vascular extracellular superoxidedismutase by nitric oxide and exercise training [J ].The Journal of Clinical Investigation, 2000,105 ( 11 ) : 1631-1639.
2Laufs U,Gertz K,Huang P,et al.Atorvastatin upregulates type Ⅲ nitric oxide synthase in thrombocytes,decreases platelet activation,and protects from cerebral ischemia in normocholesterolemic mice[J].Stroke,2000,31(10):2442-249.
3Gertz K,Laufs U,Lindauer U,et al.Withdrawal of statin treatment abrogates stroke protection in mice[J].Stroke,2003,34:551-557.
4Eto M,Kozai T,Cosentino F,et al.Statin prevents tissue factor expression in human endothelial cells:role of Rho／Rho-kinase and Akt pathways[J].Circulation,2002,105:1756-1759.
5Rosenson RS.Brown AS.Statin use in acute coronary syndromes:cellular mechanism and clinical evidence[J].Curr Opin Lipidol,2002,13:625—630.
6Son JW.Koh KK.Ahn JY,et al.Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease[J].Int J Cardiol,2003,88(1):77—82.
7Undas A, Brummel KE, Musial J, et al . Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V ,and factor Ⅻ and by enhancing factor V a inactivation[J]. Grculation ,2001,103(18) :2248-2253.
8Musial J, Undas A, Undas R, et al . Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels[J]. Thromb Haemost , 2001,85 : 221-225.
9Morishita E, Minami S,Ishino C, et al . Atorvastatin reduces plasma levels of factor Ⅶ activity and factor Ⅶ antigen in patients with hyperlipidemia[J]. J Atheroscler Thromb , 2002,9:72-77.
10Olivotti L, Ghiglitti G, Spallarossa P, et al . High dose of atorvastatin do not affect activity of prothrombinases with acute coronary syndromes[J]. Blood Coagul Fibrinolysis ,2002,13:315-322.
